Veracyte Moves Into Lung Cancer MolDx With $21 Million Allegro Buy
This article was originally published in The Gray Sheet
The molecular diagnostic firm is expanding its focus beyond thyroid cancer to lung cancer, with plans to acquire Allegro Diagnostics and its gene expression assay. Allegro’s in-development system offers enhanced risk assessment for the approximately 40 percent of bronchoscopies that are inconclusive for lung cancer.
You may also be interested in...
As more people become eligible for routine annual lung cancer screenings, Veracyte says its Percepta bronchial genomic classifier lung cancer test provides a less invasive test than biopsies and more reliability than bronchoscopy alone, according to newly published data.
FDA said its new plan, which can’t be released as a formal draft guidance for another 60 days, would establish a more level playing field between test-kit makers and labs, while being flexible when there is not an FDA-approved alternative to an lab-developed test.
Veracyte has launched a complex molecular diagnostic test in thyroid in record time and with impressive capital efficiency. It could be a model for high-value diagnostics, especially if the company can successfully adopt its approach in a broader market.